Altor Bioscience Announces NCI Phase II SBIR Grant Award and Publication Supporting Ongoing Clinical Trial of IL-15 Super Agonist ALT-803 in Combination with Anti-CD20 Antibody Therapy for Relapsed / Refractory Non-Hodgkin L